HMOX1 and diabetes mellitus: Thus, the ability of canagliflozin to evoke anti-inflammatory effects via HO-1 may contribute to its beneficial cardiovascular profile, whereas the negative, HO-1-independent effects of canagliflozin on EC growth and motility may promote an elevated risk for limb amputation in diabetes [16].